Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
In 1999 Active Biotech began studying a series of Oxigene's benzamide substances, under a joint research agreement. The outcome of this research has produced a number of positive leads within Active...
-
Active Biotech tecknade 1999 ett samarbetsavtal med Oxigene, som innebar att Active Biotech skulle utvärdera en rad av Oxigenes benzamidsubstanser. Detta forskningssamarbete har resulterat i ett antal...
-
Active Biotech's application for the initiation of TTS (Tumour Targeted Superantigens) Phase II clinical trial has been approved by UK authorities. The Principal Investigator for the study will be...
-
Active Biotechs ansökan om Fas II klinisk prövning för TTS(Tumour Targeted Superantigens)-projektet har godkänts av brittiska myndigheter. Principal Investigator för studien blir professor Robert...
-
* International expertise to lead SAIK-MS effect studies (Phase II) * Permission to start TTS Phase II trials in the UK expected shortly (renal cancer) * Progress in the cooperation with the Johns...
-
* Internationell expertis leder effektstudier (Fas II) avseende SAIK-MS * Tillstånd väntas inom kort för start av TTS Fas II-prövningar i Storbritannien (njurcancer) * Framgångar för samarbetet med...
-
For release content, please refer to the attachment....
-
The Principal Investigator of the SAIK-MS Phase II study will be Professor Chris Polman at VU Medical Centre in Amsterdam, the Netherlands. Chris Polman is Professor of Neurology at the Free...
-
Professor Chris Polman på VU Medical Centre i Amsterdam, Holland, blir Principal Investigator för den kommande Fas II-studien av Active Biotechs läkemedel mot MS, SAIK-MS. Chris Polman är professor i...
-
The Principal Investigator of the SAIK-MS Phase II study will be Professor Chris Polman at VU Medical Centre in Amsterdam, the Netherlands. Chris Polman is Professor of Neurology at the Free...